Cocrystal Pharma completes dosing in norovirus challenge study of CDI-988Sep 9Clinical readoutCDI-988Cocrystal Pharma, Inc.
Cocrystal Pharma posts Phase 1 results for CDI-988, an oral SARS-CoV-2 antiviral candidateAug 19Trial updateCDI-988Cocrystal Pharma, Inc.
Cocrystal Pharma confirms $5 million OPKO Health private placement in 8-K filingAug 3Clinical readoutCDI-988Cocrystal Pharma, Inc.
Sign inSign in